Sablayrolles B, Sanz M T, Mas B, Dutau G, Rochiccioli P
Sem Hop. 1984 Jan 19;60(2):106-11.
The results of treatment with human growth hormone in 31 children with hypopituitarism are reported. 19 boys and 12 girls were treated for several years, six years in three instances. Pituitary insufficiency was idiopathic in 23 cases (isolated in 11 and associated with other deficiencies in 12) and secondary in 8 cases. The mean statural gain during the first year of treatment was 6.3 +/- 2.2 cm with a mean dosage of 9.3 +/- 4 mg/kg/year. The parameters which have the most bearing on statural gain during the first year are: dosage (p less than 0.001) which must be at least equal to 8 mg/kg/year, bone age and chronologic age. In subsequent years statural gain is less significant and seems to be dependent upon the same parameters.
报告了31例垂体功能减退患儿使用人生长激素的治疗结果。其中19名男孩和12名女孩接受了数年治疗，有3例治疗了6年。垂体功能不全在23例中为特发性（11例为孤立性，12例伴有其他缺陷），8例为继发性。治疗第一年的平均身高增长为6.3±2.2厘米，平均剂量为9.3±4毫克/千克/年。对第一年身高增长影响最大的参数是：剂量（p<0.001），必须至少等于8毫克/千克/年，骨龄和实际年龄。在随后几年中，身高增长不太显著，似乎也取决于相同的参数。
